Target Price | $4.59 |
Price | $1.04 |
Potential |
341.35%
register free of charge
|
Number of Estimates | 12 |
12 Analysts have issued a price target Fate Therapeutics, Inc. 2026 .
The average Fate Therapeutics, Inc. target price is $4.59.
This is
341.35%
register free of charge
$12.60
1,111.54%
register free of charge
$2.02
94.23%
register free of charge
|
|
A rating was issued by 18 analysts: 9 Analysts recommend Fate Therapeutics, Inc. to buy, 9 to hold and 0 to sell. | |
Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
Analyst Estimates: Analysts believe that the Fate Therapeutics, Inc. stock has an average upside potential 2026 of
341.35%
register free of charge
|
Dec '24 |
2025 Estimates |
|
---|---|---|
Revenue Million $ | 13.63 | 7.04 |
78.55% | 48.36% | |
EBITDA Margin | -1,295.52% | -2,535.22% |
377.88% | 95.69% | |
Net Margin | -1,366.54% | -1,909.17% |
439.47% | 39.71% |
16 Analysts have issued a sales forecast Fate Therapeutics, Inc. 2025 . The average Fate Therapeutics, Inc. sales estimate is
This results in the following potential growth metrics:
5 Analysts have issued an Fate Therapeutics, Inc. EBITDA forecast 2025. The average Fate Therapeutics, Inc. EBITDA estimate is
This results in the following potential growth metrics and future EBITDA Margins:
16 Fate Therapeutics, Inc. Analysts have issued a net profit forecast 2025. The average Fate Therapeutics, Inc. net profit estimate is
This results in the following potential growth metrics and future Net Margins:
Dec '24 |
2025 Estimates |
|
---|---|---|
Earnings Per Share $ | -1.64 | -1.17 |
0.00% | 28.66% | |
P/E | negative | |
EV/Sales | negative |
16 Analysts have issued a Fate Therapeutics, Inc. forecast for earnings per share. The average Fate Therapeutics, Inc. EPS is
This results in the following potential growth metrics and future valuations:
Fate Therapeutics, Inc....
Analyst | Rating | Action | Date |
---|---|---|---|
Wells Fargo |
Locked
➜
Locked
|
Locked | Aug 13 2025 |
Needham |
Locked
➜
Locked
|
Locked | Jun 12 2025 |
Baird |
Locked
➜
Locked
|
Locked | May 14 2025 |
Barclays |
Locked
➜
Locked
|
Locked | May 14 2025 |
Needham |
Locked
➜
Locked
|
Locked | May 14 2025 |
Needham |
Locked
➜
Locked
|
Locked | Mar 06 2025 |
Stifel |
Locked
➜
Locked
|
Locked | Mar 06 2025 |
Analyst Rating | Date |
---|---|
Locked
Wells Fargo:
Locked
➜
Locked
|
Aug 13 2025 |
Locked
Needham:
Locked
➜
Locked
|
Jun 12 2025 |
Locked
Baird:
Locked
➜
Locked
|
May 14 2025 |
Locked
Barclays:
Locked
➜
Locked
|
May 14 2025 |
Locked
Needham:
Locked
➜
Locked
|
May 14 2025 |
Locked
Needham:
Locked
➜
Locked
|
Mar 06 2025 |
Locked
Stifel:
Locked
➜
Locked
|
Mar 06 2025 |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.